{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:29:20Z","timestamp":1794022160599,"version":"4.8.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The American Thoracic Society convened an international, multidisciplinary panel to develop clinical practice guidelines for the treatment of systemic sclerosis\u2013associated interstitial lung disease (SSc-ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct a systematic review and evaluate the literature to determine whether patients with SSc-ILD should be treated with cyclophosphamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature search was conducted across the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases through June 2022 for studies using cyclophosphamide to treat patients with SSc-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction<\/jats:title>\n                    <jats:p>Mortality, disease progression, quality of life, and adverse event data were extracted, and meta-analyses were performed when possible. The Grading of Recommendations, Assessment, Development and Evaluation Working Group method was used to assess the quality of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Synthesis<\/jats:title>\n                    <jats:p>Five studies were included; two randomized controlled trials compared cyclophosphamide versus placebo, and one randomized controlled trial and two retrospective case-control studies compared cyclophosphamide versus mycophenolate. Compared with placebo, there was a 2.83% reduction in the decline at 12\u2009months for forced vital capacity (FVC) % predicted using cyclophosphamide (95% confidence interval [CI], 0.80\u20134.87; low evidence). There were improvements in breathlessness (Transition Dyspnea Index mean difference [MD], 2.90; 95% CI, 1.94\u20133.86; minimum clinically important difference, 1; moderate evidence) and disability (Health Assessment Questionnaire\u2013Disability Index MD, \u22120.16; 95% CI, \u22120.28 to \u22120.04; minimum clinically important difference, \u22120.14; moderate evidence). There were increased risks of leukopenia and constitutional symptoms using cyclophosphamide, but no difference in mortality. When cyclophosphamide was compared with mycophenolate, there were differences in diffusing capacity of the lung for carbon monoxide % predicted favoring mycophenolate at 6\u2009months (MD, \u22123.67%; 95% CI, \u22126.3% to \u22121.1% unadjusted; MD, \u22124.88%; 95% CI, \u22127.3% to \u22122.5% adjusted for alveolar volume; moderate evidence), 12\u2009months (MD, \u22125.90%; 95% CI, \u22128.4% to \u22123.4% adjusted for alveolar volume; moderate evidence), and 18\u2009months (MD, \u22123.26%; 95% CI, \u22126.1% to \u22120.4%; moderate evidence), but not at 24\u2009months. There were no differences in FVC % predicted, mortality, or quality-of-life outcomes, but participants were more likely to prematurely discontinue cyclophosphamide compared with mycophenolate (relative risk, 1.70; 95% CI, 1.10\u20132.63; high-certainty evidence).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A review of the published evidence shows that cyclophosphamide is effective in SSc-ILD compared with placebo, with an increased risk of side effects. However, mycophenolate may be equivocal or better than cyclophosphamide. Clinicians and patients should weigh the potential benefits and risks with respect to individual patient circumstances and preferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202301-053oc","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T10:02:19Z","timestamp":1695981739000},"page":"122-135","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":22,"title":["Cyclophosphamide in Patients with Systemic Sclerosis\u2013Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-4191","authenticated-orcid":false,"given":"Hayley","family":"Barnes","sequence":"first","affiliation":[{"name":"Clinical School and"},{"name":"Centre for Occupational and Environmental Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6822","authenticated-orcid":false,"given":"Marya","family":"Ghazipura","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, ZS Associates, New York, New York"},{"name":"Divisions of Epidemiology and Biostatistics, Department of Population Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-8128","authenticated-orcid":false,"given":"Derrick","family":"Herman","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, The Ohio State Wexner Medical Center, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-9587","authenticated-orcid":false,"given":"Madalina","family":"Macrea","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Salem Veterans Affairs Medical Center, Salem, Virginia"},{"name":"Department of Medicine, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-3833","authenticated-orcid":false,"given":"Shandra L.","family":"Knight","sequence":"additional","affiliation":[{"name":"Strauss Health Sciences Library, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-3278","authenticated-orcid":false,"given":"Richard M.","family":"Silver","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-6808","authenticated-orcid":false,"given":"Sydney B.","family":"Montesi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-6643","authenticated-orcid":false,"given":"Ganesh","family":"Raghu","sequence":"additional","affiliation":[{"name":"Center for Interstitial Lung Diseases, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1995-7828","authenticated-orcid":false,"given":"Tanzib","family":"Hossain","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University Grossman School of Medicine, New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,1]]},"reference":[{"key":"2026012203134519300_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"key":"2026012203134519300_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026012203134519300_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir Investig"},{"key":"2026012203134519300_bib4","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2026012203134519300_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"2026012203134519300_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2397198320915042","article-title":"Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease","volume":"6","author":"Volkmann","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"2026012203134519300_bib7","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1513\/AnnalsATS.201606-426FR","article-title":"Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies","volume":"13","author":"Volkmann","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203134519300_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"key":"2026012203134519300_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"key":"2026012203134519300_bib10","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026012203134519300_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"key":"2026012203134519300_bib12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s13665-012-0028-7","article-title":"Connective tissue disease-associated interstitial lung disease: a review","volume":"1","author":"Gutsche","year":"2012","journal-title":"Curr Respir Care Rep"},{"key":"2026012203134519300_bib13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/ard.2007.075721","article-title":"The relationship of dyspnoea to function and quality of life in systemic sclerosis","volume":"67","author":"Baron","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2026012203134519300_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2026012203134519300_bib15","volume-title":"StatPearls","author":"Ogino","year":"2023"},{"key":"2026012203134519300_bib16","first-page":"CD010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012203134519300_bib17","doi-asserted-by":"crossref","first-page":"w14030","DOI":"10.4414\/smw.2014.14030","article-title":"Cyclophosphamide: as bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases","volume":"144","author":"Dan","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"2026012203134519300_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2026012203134519300_bib19","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD): evidence-based recommendations","author":"Raghu","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203134519300_bib20","author":"Higgins","year":"2022"},{"key":"2026012203134519300_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026012203134519300_bib22","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203134519300_bib23","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203134519300_bib24","author":"Higgins","year":"2022"},{"key":"2026012203134519300_bib25","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026012203134519300_bib26","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"2026012203134519300_bib27","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2026012203134519300_bib28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026012203134519300_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12961-018-0320-2","article-title":"The GRADE Evidence to Decision (EtD) framework for health system and public health decisions","volume":"16","author":"Moberg","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"2026012203134519300_bib30","article-title":"Using systematic reviews in guideline development: the GRADE approach","author":"Zhang","year":"2018","journal-title":"Res Synth Methods"},{"key":"2026012203134519300_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Sch\u00fcnemann","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203134519300_bib32","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012203134519300_bib33","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026012203134519300_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","article-title":"Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis","volume":"18","author":"Shenoy","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026012203134519300_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"key":"2026012203134519300_bib36","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/annrheumdis-2015-208929","article-title":"Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment","volume":"75","author":"Kim","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026012203134519300_bib37","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1183\/09031936.06.00032605","article-title":"Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis","volume":"28","author":"Antoniou","year":"2006","journal-title":"Eur Respir J"},{"key":"2026012203134519300_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026012203134519300_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjmed.2010.12.009","article-title":"Adverse events during the Scleroderma Lung Study","volume":"124","author":"Furst","year":"2011","journal-title":"Am J Med"},{"key":"2026012203134519300_bib40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203134519300_bib41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1513\/AnnalsATS.202301-054OC","article-title":"Mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Herman","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203134519300_bib42","article-title":"Rituximab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","author":"Macrea","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203134519300_bib43","article-title":"Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","author":"Ghazipura","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203134519300_bib44","article-title":"Nintedanib therapy alone and combined with mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: systematic reviews and meta-analysis","author":"Herman","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203134519300_bib45","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/1\/122\/66009914\/annalsats_21_1_122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/1\/122\/66009914\/annalsats_21_1_122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:14:45Z","timestamp":1769069685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/1\/122\/8382103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202301-053oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1,1]]},"assertion":[{"value":"2023-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}